Harald Reinhart - Jan 1, 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Stock symbol
ZLAB
Transactions as of
Jan 1, 2024
Transactions value $
-$125,464
Form type
4
Date filed
1/3/2024, 07:25 PM
Previous filing
Jun 26, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +17.5K +52.67% 50.9K Jan 1, 2024 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale -$125K -4.8K -9.44% $26.12 46.1K Jan 3, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Performance-Based Share Units Award $0 +17.5K $0.00 17.5K Jan 1, 2024 American Depositary Shares 17.5K Direct F1, F3, F5
transaction ZLAB Performance-Based Share Units Options Exercise $0 -17.5K -100% $0.00* 0 Jan 1, 2024 American Depositary Shares 17.5K Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired on vesting of performance-based share units (PSUs). Each ADS represents ten Ordinary Shares of the issuer.
F3 Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F4 These ADSs were sold automatically to cover taxes upon vesting of PSUs.
F5 The reporting person was granted PSUs on December 1, 2021 that vest based on the satisfaction of specified performance criteria between December 1, 2021 and December 31, 2025. On January 1, 2024, the performance-based vesting conditions were confirmed for PSUs representing 17,548 ADSs.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases